
Välj din etikett
visas direkt på vialenReta + Cagri Blend
GLP-1
- Skickas från Tyskland
Beställning
- DHL med spårning
- Diskret förpackning
I korthet
Reta + Cagri Blend i siffror
Nyckeltalen från vårt lexikon.
Hela lexikonartikeln- Class
- Triple agonistGLP-1 / GIP / glucagon, + amylin analog
- Half-life
- Retatrutide around 6 dayscagrilintide around 7 to 8 days
- Form
- Lyophilisatepowder, reconstituted with BAC water
- Sizes
- 30 mg1 size in the shop
What studies show
All 5 sources in the lexicon- up to24.2 %Jastreboff et al., NEJM, 2023
- Sanyal et al., Nature Medicine, 2024
- Lau et al., The Lancet, 2021
Omdömen
Vad kunderna säger
Endast riktiga beställningar som innehöll Reta + Cagri Blend.
Alla omdömenDet finns ännu ingen labbanalys för Reta + Cagri Blend. Rösta på denLåt testa själv, vi betalar halvaAlla labbanalyser
Kunskap
Allt om Reta + Cagri Blend
Detaljerad information kommer snart.
Dosering
Laddar doseringsinformation …
Bra att ha
Vad du behöver till den
Bakteriostatiskt vatten läggs automatiskt i din varukorg. Sprutor och sudd med ett klick.
Insulinsprutor
10 st. · 5.50 €
Spritsuddar
50 st. · 10 €
Hur mycket vatten?
Enheter på sprutan för din vialstorlek.
Öppna kalkylatorn →Is the Reta + Cagri Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and cagrilintide together. Both components are in phase 3 and not approved.
Why Retatrutide and cagrilintide together?
Both act on different satiety pathways: Retatrutide on GLP-1, GIP and glucagon, cagrilintide on amylin receptors. With semaglutide as the partner, weight loss in a phase 1b trial after 20 weeks was 17.1 instead of 9.8 percent. For Retatrutide as the partner there are no data.
What do the studies of the components show?
Retatrutide alone: in TRIUMPH-1 after 80 weeks 25.0 percent less body weight on average at the highest study dose, 3.9 percent on placebo. Cagrilintide alone: up to 10.8 percent after 26 weeks in phase 2, 3.0 percent on placebo. In a substudy liver fat also fell sharply on Retatrutide.
Why is the cagrilintide share so small?
The vial contains five times as much Retatrutide as cagrilintide, because Retatrutide is the stronger and limiting part. Anyone going by the Retatrutide share stays far below the amounts used in the cagrilintide trials. Whether the small share contributes anything has not been studied.
How long do the components stay in the body?
Retatrutide had a half-life of about six days in a phase 1b study, cagrilintide 159 to 195 hours in another study, so about a week. Both fit one dose per week.
Which side effects were seen with the components?
With both, mainly gastrointestinal effects such as nausea and diarrhoea, depending on the dose. On Retatrutide heart rate rose in a dose-dependent way in phase 2. Two satiety signals together may strengthen nausea at the start, this has not been measured for this blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The RENEW trials of cagrilintide alone run until 2027. No trial of the blend is listed in the registry.
Relaterat
Relaterade produkter
Tirzepatide
Peptider · GLP-1 & fettförbränning GLP-1 & fettförbränning
10 storlekar
Labbtestad
= från 10 €/vial
Retatrutide
Peptider · GLP-1 & fettförbränning GLP-1 & fettförbränning
11 storlekar
Labbtestad
= från 16 €/vial
Semaglutide
Peptider · GLP-1 & fettförbränning GLP-1 & fettförbränning
6 storlekar
Labbtestad
= från 10 €/vial
Mazdutide
Peptider · GLP-1 & fettförbränning GLP-1 & fettförbränning
2 storlekar
= från 32 €/vial
Reta + Cagri Blend